N C RAJ & ASSOCIATES
Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II, Delhi – 110 052
Phone: +911145670059
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 021949

INDEPENDENT AUDITOR'S REPORT

To,
The Members of
Grande Etoile Pharmaceuticals Limited
New Delhi.

Dear Sir,

Report on the Audit of the Standalone Financial Statements

We have audited the **accompanying** Standalone **financial** statements of **GRANDE ETOILE PHARMACEUTICALS LIMITED** ("the Company"), which comprise the Balance Sheet as at **31/03/2026**, the Statement of Profit and Loss and Cash Flow Statement for the year ended at **31/03/2026** and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31/03/2026 and its Loss for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial Statements.

Management's Responsibility for the Financial Statements

The Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the **Annexure A** statement on the matters specified in paragraph 3 and 4 of the Order

2. As required by Section 143 (3) of the Act, we report that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit subject to:

   (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   (c) The Balance Sheet, the Statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account.

(Forming part of Independent Auditor Report (standalone financial statement) for the year 31-03-2026 of M/s. Grande Etoile Pharmaceuticals Limited)

(d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(e) On the basis of the written representations received from the directors as on **31/03/2026** taken on record by the Board of Directors, none of the directors is disqualified as **31/03/2026** from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in **"Annexure B".**

(g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company did not have any outstanding litigations as on 31st March 2026.

ii. The Company did not have any long-term contracts including derivative contracts as on 31st March 2026.

iii. As on 31st March 2026 there were no amount which were required to be transferred by the company to the Investor Education and Protection Fund in accordance with the relevant provisions.

3. The Company has maintained audit trail in its books of accounts since, as per the proviso to rule 3(1) of companies (Accounts) Rules, 2014 is applicable for company.

For N C Raj & Associates
Chartered Accountants
(FRN: 002249N)

(Sanjay Garg)
Partner
M. No. 088636
Place: New Delhi
Dated: 29-May-2026
UDIN: 26088636LMKIWV2895

"Annexure B" to the Independent Auditor's Report of even date 29th May 2026 on the Standalone Financial Statements of GRANDE ETOILE PHARMACEUTICALS LIMITED.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **GRANDE ETOILE PHARMACEUTICALS LIMITED** ("The Company") as of March 31, 2026 in conjunction with our audit of Standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls:

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and operating effectiveness of internal control based on the assessed risk. The procedures selected depend upon on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted

N C RAJ & ASSOCIATES DELHI Chartered Accountants accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issues by the Institute of Chartered Accountants of India.

For N C Raj & Associates
Chartered Accountants
(FRN: 002249N)

DELHI

(Sanjay Garg)
Partner
M. No. 088636
Place: New Delhi
Dated: 29-May-2026
UDIN: 26088636LMKIWV2895

ANNEXURE A

Reports under The Companies (Auditor's Report) Order, 2020 (CARO 2020) for the year ended on 31st March 2026

To,
The Members of
M/s Grande Etoile Pharmaceuticals Limited
New Delhi.

(1) In Respect of Property, Plant & Equipment

(a) The company has **maintained proper records** showing full particulars including quantitative details and situation of fixed assets.

(b) Fixed assets have been **physically verified** by the management at reasonable intervals; No material discrepancies were noticed on such verification.

(c) The **titles deeds** of immovable property are in the name of the company.

(d) The revaluation of Property, plant and equipment is not done by the company.

(e) There are No proceedings initiated or pending against the company for holding Benami Property under the prohibition of Benami Property Act, 1988 and rules made there under.

(2) Inventory and Working Capital

a. Physical verification of inventory and working capital has been conducted at reasonable intervals by the management, however, no stock verification report is available.

b. The company has not been sanctioned any working capital facility during the year and has no working capital facility in excess of INR 5 Crores in aggregate from banks or financial institutions at the end of the year. Hence, reporting under this clause is not applicable.

(3) According to the information and explanation given to us, during the financial year the company has made investment in one subsidiary as mentioned below: -

(a) Investment in Subsidiary
Loire Cosmetics Limited

(b) Given to other Parties
N/A

(4) The company has Complied with the provisions of section 185 and 186 of The Companies Act, 2013 relating to Loans advances investment and security given

(a) Loan given to Subsidiary
Loire Cosmetics Limited

(5) Compliance under section 73 to 76 of The Companies Act, 2013 and Rules framed thereunder while accepting Deposits

The company has not accepted any Deposit. Therefore, reporting under this clause is not applicable

(6) To the best of our knowledge and as explained, the Central Government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 for the products of the company.

N C RAJ & ASSOCIATES DELHI Chartered Accountants

(7) Deposit of Statutory Dues

a) According to the records of the company produced before us and as per the information and explanation given to us, the company is regular in depositing with the appropriate authorities' statutory dues including GST, except Income-Tax of Rs. 16.70 Lakh related to FY 2024-25 which has not been paid as on 31st March 2026.

b) There is no dispute with the revenue authorities regarding any duty or tax payable.

(8) As per the explanations and information given to us there were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(9) The company has not taken any loan from financial institution, or a bank during the year. Therefore, reporting under this clause is not applicable

(10) Utilization of Money Raised by Public Offers and Term Loan For which they Raised and Private Placement. The company has not raised money by Public Offer and Term Loan Therefore, reporting under this clause is not applicable

(11) Based on our audit procedures and the information and explanation made available to us, there is no fraud noticed or reported during the year.

(12) The company is not a Nidhi Company. Therefore, reporting under this clause is not applicable.

(13) All the transaction with the related parties are in the compliance with section 177 and 188 of the Companies Act, 2013 where applicable and the details have been disclosed in the standalone financial statement as required by the applicable Accounting Standards 18.

(14) In our opinion and according to the information and explanations given to us, though the Company is not statutory required to have an internal audit system under Section 138 of the Companies Act, 2013, it has a voluntary internal audit system which, in our opinion, is commensurate with the size and nature of its business.

Accordingly, reporting under Clause 3(xiv)(a) and (b) of the Order is not applicable.

(15) According to the information and explanations given to us, in our opinion during the year the company has not entered any non-cash transactions with its directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 and reporting under this clause are not applicable to the company.

(16) In our opinion the Company is not required to be registered under Section 45-IA of Reserve Bank of India Act, 1934. Therefore, reporting under clause 3(xvi) (a), (b) and (c) of the Order is not applicable.

(17) According to the information and explanations given to us and based on the audit procedures conducted by us, the Company **has incurred cash losses** amounting to **Rs. 97.09 lakhs** during the financial year covered by our audit and **Rs. 2.67 lakhs** in the immediately preceding financial year.

(18) There has been no resignation of the statutory auditors of the company during the year. Therefore, reporting under clause (xviii) is not applicable

DELHI

(19) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(20) The company has been incorporated in the FY 2024-25. Accordingly, reporting under clause (xx) of the order is not applicable to the company for the year.

(21) In standalone financial statements reporting under clause (xxi) of the order is not applicable.

For N C Raj & Associates
Chartered Accountants
(FRN: 002249N)

DELHI

(Sanjay Garg)
Partner
M. No. 088636
Place: New Delhi
Dated: 29-May-2026
UDIN: 26088636LMKIWV2895

GRANDE ETOILE PHARMACEUTICALS LIMITED

10, Community Centre No-2, Ashok Vihar Phase-2, Delhi-110052

CIN:- U21009DL2024PLC440529

STANDALONE BALANCE SHEET AS AT 31st MARCH 2026

In Lakhs

Particular	Note No.	Figures as at the end of 31st March 2026	Figures as at the end of 31st March 2025
Equity and Liabilities			
Shareholders' Funds			
Share Capital	2	50.00	50.00
Reserves and Surplus	3	-12.33	79.39
Current Liabilities			
Short Term Borrowing	4	88.49	-
Trade Payables	5		
(i) total outstanding dues of micro enterprises and small enterprises		-	-
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises		0.09	-
Other Current Liabilities	6	2.75	8.27
Short Term Provisions	7	16.70	26.70
Total		145.70	164.35
Assets			
Property Plant & Equipments			
Property Plant & Equipments	8	0.73	-
Intangible assets	8	8.34	-
Deffered Tax Assets		-	-
Other Non-Current Assets	9	1.45	1.78
Non- Current Investments	10	2.54	-
Current Assets			
Inventory	11	12.66	-
Trade receivables	12	65.15	110.00
Cash and Bank Balances	13	25.79	47.33
Short Term Loans and Advances	14	29.04	5.24
Total		145.70	164.35

Significant Accounting Policies and Notes to the Financial Statements **1 to 22**

As per our attached Report of Even Date
For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN : 002249N)

SANJAY GARG
Partner
Mem No. 088636
UDIN : 26088636LMKIWV2895
Date: 29-May-2026
Place: Delhi

For **and on behalf of the Board of Directors of Grande Etoile Pharmaceuticals Limited**

For Grande Etoile Pharmaceuticals Ltd. For Grande Etoile Pharmaceuticals Ltd.

Director Director

Harsh Goyal
DIN:- 10891142
Director

Vaibhav Kashinath Chaudhari
DIN:- 05270401
Director

GRANDE ETOILE PHARMACEUTICALS LIMITED

10, Community Centre No-2, Ashok Vihar Phase-2, Delhi-110052

CIN:- U21009DL2024PLC440529

STATEMENT OF STANDALONE PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2026

In Lakhs

Particular	Note No.	Figures for the year ended 31st Mar 2026	Figures for the year ended 31st March 2025
Revenue			
Revenue from Operations	15	98.06	110.00
Other Income	16	0.64	-
Total Income		**98.70**	**110.00**
Expenses			
Cost of Materials Consumed	17	52.71	-
Direct Expenses	18	8.11	-
Employee benefits expense	19	7.86	-
Finance Costs	20	0.34	0.01
Depreciation	8	0.99	-
Other Expenses	21	120.40	S
Total Expenses		**190.41**	**0.01**
Profit before Tax		-91.72	109.99
Tax Expense			
(1) Current tax		-	26.70
(2) Deferred tax		-	-
Profit for the year		**-91.72**	**83.29**
Earning per Equity Share (in Rs.)		(18.34)	33.23

Significant Accounting Policies and Notes to the Financial Statements **1 to 22**

As per our attached Report of Even Date
For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN : 002249N)

SANJAY GARG
Partner
Mem No. 088636
UDIN : 26088636LMKIWV2895
Date: 29-May-2026
Place: Delhi

For and on behalf of the Board of Directors of
Grande Etoile Pharmaceuticals Limited

For Grande Etoile Pharmaceuticals Ltd.
Director

Harsh Mittal
DIN:- 10891142
Director

For Grande Etoile Pharmaceuticals Ltd.
Director

Vaibhav Kashinath Chaudhari
DIN:- 05270401
Director

GRANDE ETOILE PHARMACEUTICALS LIMITED

10, Community Centre No-2, Ashok Vihar Phase-2, Delhi-110052

CIN:- U21009DL2024PLC440529

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH 2026

(Rs. in Lakhs)

Particulars	Figures as at the end of As At 31.03.2026	Figures as at the end of As At 31.03.2025
Cash flow from operating activities		
Net profit before taxation, and extraordinary item	-91.72	106.09
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	-	-
Depreciation/amortization on continuing operation	0.99	-
Interest expense	0.34	-
Interest income	-	-
Adjustment for Deffered Tax	-	-
Operating profit before working capital changes	**-90.39**	**106.09**
Movements in working capital :		
Increase/(decrease) in trade payables	0.09	-
Increase/(decrease) in other current liabilities	-5.51	8.27
Decrease/ (increase) in trade receivables	44.85	-110.00
Decrease/ (increase) in inventories	-12.66	-
Decrease / (increase) in other non-current Assets	0.33	-1.78
Decrease / (increase) in short-term loans and advances	-23.80	-5.24
Decrease/(increase) in other current assets	-	-
Direct taxes paid (net of refunds)	-10.00	-
Net cash flow from/ (used in) operating activities (A)	**-97.09**	**-2.67**
Cash flows from investing activities		
Purchase of fixed assets, including intangible assets and CWIP	-10.06	-
Purchase of non-current investments	-2.54	-
Interest received	-	-
Net cash flow from/(used in) investing activities (B)	-12.60	-
Cash flows from financing activities		
Proceeds from issuance of share capital	-	50.00
Proceeds from Short term Borrowing	88.49	
Proceeds from Securities Premium	-	-
Interest paid	-0.34	-
Net cash flow from/(used in) in financing activities (C)	**88.15**	**50.00**
Net increase/(decrease) in cash and cash equivalents (A + B + C)	**-21.54**	**47.33**
Cash and cash equivalents at the beginning of the year (D)	47.33	-
Cash and cash equivalents at the end of the year (E)	25.79	47.33
Difference in above D and E	**-21.54**	**47.33**

Significant Accounting Policies and Notes to the Financial Statements 1 to 22

As per our attached Report of Even Date
For N C RAJ & ASSOCIATES
Chartered Accountants
FRN : 002249N

For & on behalf of the Board of Directors

For Grande Etoile Pharmaceuticals Ltd. For Grande Etoile Pharmaceuticals Ltd

Director Director

SANJAY GARG
Partner
Membership No.: 088636
UDIN : 26088636LMKIWV2895
Place : New Delhi
Date: 29-May-2026

Harsh Mittal
DIN:- 10891142
Director

Vaibhav Kashinath Chaudhari
DIN:- 05270401
Director

NOTE : 1

1 COMPANY OVERVIEW :

Grande Etoile Pharmaceuticals Limited ("the Company") was incorporated under the Companies Act, 2013. The Registered Office of the Company is situated at Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi - 110052. The company is engaged in the business of trading of Pharmaceutical and allied products.

2 SIGNIFICANT ACCOUNTING POLICIES

(a) Method of Accounting:

The financial statements are prepared in accordance with the Generally Accepted Accounting Principles in India ('Indian GAAP') to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on accrual basis. All amounts included in the financial statements are reported in lakhs upto two decimal of Indian Rupees.

(b) Presentation and disclosure of financial statements:

During the year ended 31st March 2026, the Company has presented the financial statements as per the Schedule III notified under the Companies Act, 2013. The Company has also reclassified the previous figures in accordance with the requirements applicable in the current year.

(c) Use of estimates:

The preparation of financial statements requires management to make judgments, estimates and assumptions in the application of accounting policies that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, if any at the end of the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(d) Inventories (AS 2):

Inventories of Pharmaceuticals products is valued at the lower of cost and estimated net realizable value, whereas invetory is

valued at cost (first in first out basis) or realizable value whichever is lower. The company does not have inventory as at 31-03-2025

(e) Cash and Cash Equivalents (AS 3):

Cash and cash equivalents for the purpose of cash flow statement comprise cash at bank and in hand, cheque on hand and short-term investments with an original maturity of three months or less.

(f) Revenue recognition (AS 9):

Sale:-

Revenue from sale of goods is recognized in the statement of profit and loss when the significant risks and rewards in respect of ownership of goods has been transferred to the buyer as per the terms of the respective sales order, and the income can be measured reliably and is expected to be received.

Interest:-

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable. The company does not have interest income for the year ended 31-03-2025

(g) AMORTIZATION:

Preliminary expenses are to be written off in 5 annual equal installments. So the company has incurred pre incorporation expenses and written off in 5 equal installment and FY 2024-25 considered as first year.

DELHI

For Grande Etoile Pharmaceuticals Ltd

Director

For Grande Etoile Pharmaceuticals Ltd

Director

(h) **FIXED ASSETS, INTANGIBLE ASSETS AND CAPITAL WORK IN PROGRESS:**

Fixed assets are stated at cost, less accumulated depreciation. Direct costs are capitalized until fixed assets are ready for use.

Capital Work in progress comprises of the cost of fixed assets that are not yet ready for their intended use at the reporting date.

Fixed assets are stated at their cost of acquisition and less accumulated depreciation and accumulated impairment loss, if any. The cost of fixed assets includes cost of acquisition plus, freight, taxes, duties and other incidental expenses including interest paid up to commercial use of assets that are directly attributable to bring the assets to their working conditions for their intended use.

the company does not have any Fixed assets during the year.

(i) **Research & Development:**

Research costs are expensed as incurred. Software product development costs are expensed as incurred unless technical and commercial feasibility of the project is demonstrated, future economic benefits are probable, the company has an intention and ability to complete and use or sell the software and the cost can be measured reliably.The Company has not incurred any expense on Research & Development during the year.

(j) **Foreign Exchange Transactions (AS 11):**

The company has policy to recognize difference in foreign currency in relation to material in Profit & Loss account and relating to Fixed Assets addition to Fixed Asset, however there was no purchase of fixed asset against which liability has been created in foreign currency. The company has transferred difference in foreign exchange to Profit & Loss Account, because those related to purchase and sale of material.

(k) **Government grants and subsidies (AS 12):**

Grants and subsidies from the government are recognized when there is reasonable assurance that (i) the Company will comply with the conditions attached to them, and (ii) the grant / subsidy will be received.

(l) **Investments (AS 13):**

Investments which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. If an investment is acquired, or partly acquired, by the issue of shares or other securities, the acquisition cost is the fair value of the securities issued.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. On disposal of an investment, if any, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

(m) **Retirement and other Employee benefits (AS 15):**

Defined contributions to Provident Fund are charged to the statement of Profit & Loss of the year, when the employee renders the related service. There are no other obligations other than the contribution payable to the respective statutory authorities.

No retirement benefits have been paid to any employees during the year by the Company except the eligible employee leaving the organisation. Retirement benefits in the form of Gratuity and leave encashment of employee benefits have been provided for its employees, based on the actuarial valuation obtained by the company from registered actuarial.

(n) **Borrowing Costs (AS 16):**

Loan processing charges paid to bank for bank cash credit facilities and Mortgage Loan have been charged to revenue account since the same are not attributable to the acquisition of qualifying assets as per the requirements of AS 16. Borrowing cost primarily includes interest and amortization of ancillary costs incurred in connection with the arrangement of borrowings.

DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

(o) **Operating leases (AS 19):**

Where the Company is a lessee:

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on the basis of the lease (rent agreements). Initial direct costs such as legal costs, brokerage costs, etc. if any, are recognized immediately in the statement of profit and loss.

Where the Company is a lessor:

Rental income from operating lease is recognized on a straight-line basis over the term of the relevant lease except where another systematic basis is more representative of the time pattern of the benefit derived from the asset given on lease.; or the payments to the lessor are structured to increase in line with expected general inflation to compensate for the lessor's expected inflationary cost increases.

(p) **Earning / (loss) per share (AS 20):**

Basic earnings / (loss) per share is computed by dividing the net profit / (loss) for the period attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period.

The weighted average number of equity shares outstanding during the period are adjusted for any bonus shares issued during the year and also after the balance sheet date but before the date the financial statements are approved by the board of directors for the purpose of calculating diluted earnings / (loss) per share. The net profit / (loss) for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares as appropriate. The dilutive potential equity shares are adjusted for the proceeds receivable, had the shares been issued at fair value. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date.

(q) **Taxation (AS 22):**

Tax expense comprises current and deferred tax. Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted at the reporting date.

Deferred tax liabilities are recognized for all taxable timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized. The carrying amount of deferred tax assets are reviewed at each reporting date.

The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

For Grande Etoile Pharmaceuticals Ltd

Director

For Grande Etoile Pharmaceuticals Ltd

Director

(.r) Provisions and contingent liabilities, Contingent assets (AS 29):

A provision is recognized when the Company has a present obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation and in respect of which a reliable estimate can be made of the amount of obligation. Provisions are not discounted to their present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These estimates are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

Provisions of various expenses are recognized in the financial statements since there exists present obligations as a result of event and the expenses are accrued and incurred during the year.

The opening balance of provisions is used during the year against the payments during the year. The closing balances of provisions are the expenses accrued during the year and provided.

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably.

N C RAJ & ASSOCIATES Chartered Accountants DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

GRANDE ETOILE PHARMACEUTICALS LIMITED
NOTES TO THE STANDALONE FINANCIAL STATEMENTS AS AT 31st MARCH 2026

2 **Share Capital**

	Figures As at 31st March 2026	Figures As at 31st March 2025
		In Lakhs
Authorised		
10,00,000 Equity Shares of Rs.10/- each	100.00	100.00
Issued, Subscribed and Paid up		
5,00,000 Equity Shares of Rs.10/- each	50.00	50.00
	50.00	**50.00**

Shares Reconciliation Statement

Particulars	Figures As at 31st March 2026		Figures As at 31st March 2025	
	Number of Shares	Amount	Number of Shares	Amount
Equity Shares, fully Paid up				
Balance as at beginning of the year	5.00	50.00	-	-
Add:- Equity Shares issued during the year	-	-	5.00	50.00
Balance as at end of the year	5.00	50.00	5.00	50.00

Right, preference and restriction attached to shares

Equity Shares : The Company has one class of equity shares having a par value of Rs.10/- per share. Each shareholder is eligible for one vote per share held.

Details of Shareholders holding more than 5% of Paid up Equity Share Capital

Particulars	Figures As at 31st March 2026		Figures As at 31st March 2025	
Equity Shares	Percentage	No of Shares	Percentage	No of Shares
Medicamen Organics Limited	50.92	2,54,600	50.92	2,54,600
Madhuri Vaibhav Chaudhari	4.00	20,000	4.00	20,000
Harsh Mittal	20.00	1,00,000	20.00	1,00,000
Poonam Mittal	4.00	20,000	4.00	20,000
Vaibhav Kashinath Chaudhari	21.00	1,05,000	21.00	1,05,000
Gaurav Kumar	0.04	200	0.04	200
Jitender Pednekar	0.04	200	0.04	200
Total	**100.00**	**5,00,000**	**100.00**	**5,00,000**

Details of Shareholdings of Promoters

Shareholders	Figures As at 31st March 2026		Figures As at 31st March 2025	
Equity Shares	No.Of Shares	Percentage	No.Of Shares	Percentage
Medicamen Organics Limited	2,54,600	50.92%	2,54,600	50.92%
Harsh Mittal	1,00,000	20.00%	1,00,000	20.00%
Vaibhav Kashinath Chaudhari	1,05,000	21.00%	1,05,000	21.00%

3 **Reserves and Surplus**

Surplus in Statement of Profit and Loss	Figures As at 31st March 2026	Figures As at 31st March 2025
Balance as at the beginning of the year	79.39	-
Add: Profit / (Loss) for the year	-91.72	79.39
Balance as at the end of the year	-12.33	79.39

For Grande Etoile Pharmaceuticals Ltd

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

GRANDE ETOILE PHARMACEUTICALS LIMITED

NOTES TO THE STANDALONE FINANCIAL STATEMENTS AS AT 31st MARCH 2026

(Rs. in Lakhs)

4 Short Term Borrowing

	Figures As at 31st March 2026	Figures As at 31st March 2025
Unsecured loan from Related Party	88.49	-
	88.49	-

5 Trade Payables

	AS AT 31st March 2026					
	Unbilled Dues	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-	-
ii) Others		0.09	-	-	-	0.09
(iii) Disputed dues— MSME	-	-	-	-	-	-
(iv) Disputed dues— Others	-	-	-	-	-	-
	-	0.09	-	-	-	0.09

Trade Payables

	AS AT 31st MARCH 2025					
	Unbilled Dues	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-	-
ii) Others	-	-	-	-	-	-
(iii) Disputed dues— MSME	-	-	-	-	-	-
(iv) Disputed dues— Others	-	-	-	-	-	-
	-	-	-	-	-	-

6 Other Current Liabilities

	Figures As at 31st March 2026	Figures As at 31st March 2025
Statutory Dues (TDS, GST ,EPF, ESIC & TCS)	0.36	-
Advance from Customer	1.64	7.79
Employee benefit payable	0.15	-
Imprest from Director and Employee	0.30	0.18
Bank Interest Payable	0.00	-
Audit Fees Payable	0.30	0.30
	2.75	8.27

7 Short Term Provisions

	Figures As at 31st March 2026	Figures As at 31st March 2025
Provision for Income Tax	16.70	26.70
	16.70	26.70

9 OTHER NON-CURRENT ASSETS

	Figures As at 31st March 2026	Figures As at 31st March 2025
Pre-Incorporation Expense	1.33	1.78
Security Deposits	0.11	-
	1.45	1.78

10 Non - Current Investment

	Figures As at 31st March 2026	Figures As at 31st March 2025
Investments in Loire Cosmetics Limited (Subsidiary) Subscribed 25,375 Equity Shares out of 50,000 Equity shares with Face value of Rs.10/- each shares	2.54	-
	2.54	-

DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

11 **INVENTORY**

	Figures As at 31st March 2026	Figures As at 31st March 2025
Stock in Trade	12.66	-
#Valuation is based on FIFO Method		
	12.66	**-**

12 **Trade Receivables**

(Rs. in Lakhs)

Particulars	Figures For the Current Reporting Period					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed - Considered Goods	6.31	58.84	-	-	-	65.15
Undisputed- Considered Doubtful	-	-	-	-	-	-
Disputed -Considered Goods	-	-	-	-	-	-
Disputed- Considered Doubtful	-	-	-	-	-	-
Total	**6.31**	**58.84**	-	-	-	**65.15**

Particulars	Figures For the Previous Reporting Period					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed - Considered Goods	110.00	-	-	-	-	110.00
Undisputed- Considered Doubtful	-	-	-	-	-	-
Disputed -Considered Goods	-	-	-	-	-	-
Disputed- Considered Doubtful	-	-	-	-	-	-
Total	110.00	-	-	-	-	110.00

13 **Cash and Bank Balances**

	Figures As at 31st March 2026	Figures As at 31st March 2025
Balances with Banks:		
- in current account	0.67	47.33
Cash in hand	21.91	-
Dollar (USD) in hand	3.21	-
	25.79	**47.33**

14 **Short-Term Loans and Advances**

	Figures As at 31st March 2026	Figures As at 31st March 2025
(Unsecured, considered good)		
Advance to Supplier	15.01	4.92
Balance With Revenue Authority	4.79	0.00
Reimbursement Recievable	0.31	0.31
Loan to Subsidiary - Loire Cosmetics Ltd	8.92	-
	29.04	**5.24**

DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

GRANDE ETOILE PHARMACEUTICALS LIMITED

NOTES TO THE STANDALONE FINANCIAL STATEMENTS AS AT 31st MARCH 2026

		In Lakhs	In Lakhs
15	**Revenue from Operations**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st Mar 2025**
	Revenue from Operations	98.06	110.00
		98.06	**110.00**

16	**Other Income**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st March 2025**
	Duty Drawback	0.23	-
	RODTEP Received	0.13	
	Other Income	0.14	
	Foreign Exchange Variations	0.14	
		0.64	**-**

17	**Cost Of Material Consumed**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st March 2025**
	Opening Stock	-	-
	Add: Purchases	65.37	-
	Less: Transfer to other Branch	-	-
	Less : Closing Stock	12.66	-
	Net-Cost Of Material Consumed	**52.71**	**-**

18	**Direct Expenses**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st March 2025**
	Freight	7.99	-
	Packing Expense	0.12	-
		8.11	**-**

19	**Employee Benefits Expenses**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st March 2025**
	Salaries & Allowances	7.86	-
		7.86	**-**

20	**Finance Costs**	**Figures for the year ended 31st Mar 2026**	**Figures for the year ended 31st Mar 2025**
	Bank Charges	0.34	0.01
	Interest on TDS	0.00	-
	Bank Interest on Overdraft	0.00	-
		0.34	**0.01**

NC RAJ & ASSOCIATES DELHI Chartered Accountants

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

21	Other Expenses	Figures for the year ended 31st Mar 2026	Figures for the year ended 31st Mar 2025
	Auditors' Remuneration	0.30	0.30
	Computer Expenses	0.02	-
	Communication Expense	0.51	-
	Foreign Exchange Fluctuation	-	-
	Fees and Taxes	0.36	0.04
	Misc Expense	0.03	-
	Advertisement Expense	0.40	-
	Office Expense	0.41	-
	Printing & Stationary	0.92	0.02
	Professional Charges	0.65	0.20
	Pre-Incorporation Expenses Amortisation	0.44	0.44
	Rent	2.00	-
	Tour & Travelling	4.36	2.90
	Written off	110.00	-
	Insurance		
	- Others	0.01	-
		120.40	**S**

Significant Accounting Policies and Notes to the Financial Statements **1 to 22**

As per our attached Report of Even Date
For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN : 002249N)

DELHI

SANJAY GARG
Partner
Mem No. 088636
UDIN : 26088636LMKIWV2895
Date: 29-May-2026
Place: Delhi

For **and on behalf of the Board of Directors of**
Grande Etoile Pharmaceuticals Limited

For Grande Etoile Pharmaceuticals Ltd.
Director

Harsh Mittal
DIN:- 10891142
Director

For Grande Etoile Pharmaceuticals Ltd
Director

Vaibhav Kashinath Chaudhari
DIN:- 05270401
Director

Note: 8 Schedule of Tangible Assets
As on 31.03.2026

(Rs. in Lakhs)

	GROSS BLOCK				DEPRECIATION BLOCK				NET BLOCK	
Description	Gross Value as on 01/04/2025	Addition during the Year	Adjustment during the period (RFS)	Gross Value as on 31/03/2026	Depreciation as on 01/04/2025	Deprecition during the Year	Adjustment during the period	Total as on 31/03/2026	W.D.V. as on 31/03/2026	W.D.V. as on 31/03/2025
Mobile	-	0.19	-	0.19	-	0.02	-	0.02	0.17	-
Computer	-	0.72	-	0.72	-	0.16	-	0.16	0.56	-
Total	-	0.92	-	0.92	-	0.18	-	0.18	0.73	-
Prev. Year	-	-	-	-	-	-	-	-	-	-

Note: 8 Schedule of Intangible Assets
As on 31.03.2026

(Rs. in Lakhs)

	GROSS BLOCK				DEPRECIATION BLOCK				NET BLOCK	
Description	Gross Value as on 01/04/2025	Addition during the Year	Adjustment during the period (RFS)	Gross Value as on 31/03/2026	Depreciation as on 01/04/2025	Deprecition during the Year	Adjustment during the period	Total as on 31/03/2026	W.D.V. as on 31/03/2026	W.D.V. as on 31/03/2025
Patent/Trademark	-	9.14	-	9.14	-	0.80	-	0.80	8.34	-
Total	-	9.14	-	9.14	-	0.80	-	0.80	8.34	-
Prev. Year	-	-	-	-	-	-	-	-	-	-

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

N C RAJ & ASSOCIATES
DELHI
Chartered Accountants

Note 22

NOTES TO ACCOUNTS:

1 The Company has not revalued its Property, Plant and Equipment, therefore the company shall not required to disclose as to whether the revaluation is based on the valuation by a registeredvaluer as defined under rule 2 of the Companies (Registered Valuers and Valuation) Rules, 2017

2 Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are:

(a) repayable on demand or

(b) without specifying any terms or period of repayment (In Lakhs)

Type of Borrower	Amount of loan and Advance in the nature of Loan outstanding	Percentage to the total Loans and Advances in the nature of loans
Promotors	-	-
Directors	-	-
KMPs	-	-
Related Parties	8.92	100

3 **Capital Work In Progress (CWIP)**

(a) Following ageing schedule shall be given.

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Projects in progress (Haridwar)	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

(b) whose completion is overdue or has exceeded its cost compared to its original plan, following

CWIP	To be Completed in				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Project 1	-	-	-	-	-
Project 2	-	-	-	-	-

4 Intangible assets under development:

(a) For Intangible assets under development

Instangible Assets under Development	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Project 1	-	-	-	-	-
Project 2	-	-	-	-	-

(b) Intangible assets under development completion schedule

Instangible Assets under Development	To be Completed in				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Project 1	-	-	-	-	-
Project 2	-	-	-	-	-

5 **Other Information**

Particulars	**As at 31-03-2026**	**As at 31-03-2025**
Details of Crypto Currency or Virtual Currency	NIL	NIL
Undisclosed income	NIL	NIL
Where a company has received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall	NIL	NIL
Utilisation of Borrowed funds and share premium	NIL	NIL
Compliance with approved Scheme(s) of Arrangements	NIL	NIL
Compliance with number of layers of companies	NIL	NIL
Registration of charges or satisfaction with Registrar of Companies (ROC)	NIL	NIL
Relationship with Struck off Companies	NIL	NIL
Wilful Defaulter*	NIL	NIL
Details of Benami Property held	NIL	NIL
Title deeds of Immovable Property not held in name of the Company	NIL	NIL

6 **CONTINGENT LIABILITIES** (In Lakhs)

Particulars	**As at 31-03-2026**	**As at 31-03-2025**
a. Cases against the company	-	-
b. Margin money (FDR) for Bank Guarantee	-	-

DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

7 **EARNING PER SHARE**

(In Lakhs)

Particulars	As at 31-03-2026	As at 31-03-2025
Profit attributable to equity shares	-91.72	83.29
Weighted Average No. of shares(Excluding potential shares)	5.00	2.51
Weighted Average No. of shares(Including potential shares)	5.00	2.51
Basic Earning Per Share	(18.34)	33.23
Diluted Earning Per Share	(18.34)	33.23

8 Where the Company has borrowings from banks or financial institutions on the basis of current assets: - The Company has no borrowings.

(a) whether quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts.	Not Applicable
(b) if not, summary of reconciliation and reasons of material discrepancies, if any to be adequately disclosed	Not Applicable

11 Registration of charges or satisfaction with Registrar of Companies **Not Applicable**

Where any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period, details and reasons thereof shall be disclosed.

12 Compliance with number of layers of companies **Not applicable**

Where the company has not complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017, the name and CIN of the companies beyond the specified layers and the relationship/extent of holding of the company in such downstream companies shall be disclosed.

13 **Ratios**

Ratios	Numerator	Denominator	Current Reporting Period	Previous reporting period	% of Change
Debt Equity Ratio	Debt Capital (Non- current liab + Short term borrowing)	Shareholder's Equity (total of Equity share holders funds)	2.35	-	-2.35
Debt Service coverage ratio	EBIT	Debt Service (Int+Principal) (Short term only axis +Long term borowing except CC and OD Loan)	-	-	-
Return on Equity Ratio	Profit for the year	Average Shareholder's Equity	(109.81)	64.38	174.18
Inventory Turnover Ratio	COGS	Average Inventory	8.33	-	-8.33
Trade Receivables turnover ratio	Net Sales	Average trade receivables	1.13	1.00	-0.13
Trade payables turnover ratio	Total Purchases (Cost of Material Consumed)	Average Trade Payables	1,152.44	-	-1,152.44
Net Capital Turnover Ratio	Sales	Workimg capital (CA-CL)	4.01	0.86	-3.15
Net profit ratio	Net Profit	Sales	(92.93)	75.72	168.65
Return on Capital employed	Earnings before interest and tax	Capital Employed (share holder funds+long term borrowing+deferred tax+ short term borrowing)	(77.56)	85.02	162.58
Return on investment #	Net Profit	Investment	NA	NA	NA

 # we do not have any investment

14 Compliance with approved Scheme(s) of Arrangements Not applicable

Where any Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013, the Company shall disclose that the effect of such Scheme of Arrangements have been accounted for in the books of account of the Company 'in accordance with the Scheme' and 'in accordance with accounting standards' and deviation in this regard shall be explained

15 Utilisation of Borrowed funds and share premium:

a. Transactions where an entity has provided any advance, loan, or invested funds to any other person (s) or entity/ entities, including foreign entities. Not Applicable

b. Transactions where an entity has received any fund from any person (s) or entity/ entities, including foreign entity Not Applicable

16 **Micro Small and Medium Enterprises**

The company has received intimation from Suppliers regarding their status under the Micro Small and Medium Enterprises Development Act, 2006, and disclosures relating to the amount unpaid as at the year-end, as required under the said Act, have been provided. the company does not have any trade payables.

DELHI

For Grande Etoile Pharmaceuticals Ltd.

Director

For Grande Etoile Pharmaceuticals Ltd.

Director

17 **Related Party Disclosure**

Related Party disclosures as required by Accounting Standard 18, "Related Party Disclosure", issued by the Institute of Chartered Accountants of India are given below:-

(In Lakhs)

Party's Name	Relation	Nature of transaction	Transactions	Outstanding as on 31-03-2026	Outstanding as on 31-03-2025
Medicamen Organics Limited	Holding Company	Investment	-	25.46	25.46
		Loan Taken	50.46	50.46	-
		Reimbursement of Expenses	-	0.31	0.31
Jitender Pednekar	Director	Tour and trevelling reimbursement	-	-	0.18
Harsh Mittal	Director	Loan Taken	27.15	27.15	-
		Reimbursement of Expenses	0.30	0.30	-
Vaibhav Kashinath Chaudhari	Director	Loan Taken	7.00	7.00	-
Loire Cosmetics Limited	Subsidiary Company	Loan Given	8.93	8.93	-

18 **CIF VALUE OF IMPORTS** (In Lakhs)

Particular	As at 31-03-2026	As at 31-03-2025
Raw Materials	-	-

19 **EXPENDITURE IN FOREIGN CURRENCY** (In Lakhs)

Particular	As at 31-03-2026	As at 31-03-2025
Raw Materials	-	-
Foreign Travelling	1.26	2.90

20 **FOB VALUE OF EXPORTS**	77.65	110.00
21 **INCOME IN FOREIGN CURRENCIES**	-	-

22 **Note on Write-off of Receivable from Medi Hub Organic Limited (Nepal)**

During the financial year, Grande Etoile Pharmaceuticals Limited (Subsidiary of Medicamen Organics Limited) had written off of Rs. 110 Lakhs, invoice raised in the FY 2024-25 to Medi Hub Organic Limited, Nepal towards provision of Consultancy Services relating to Design, Construction, Documentation, Product Development and Technology Transfer.

Accordingly, the outstanding receivable of ₹110 Lakhs (Rupees One Crore Ten Lakhs Only) from Medi Hub Organic Limited (Nepal) has been written off in [illegible]

23 Unhedged Foreign Currency Outstanding as on 31-03-2026 is Rs.4,66,432.01 (USD 4944.10).

24 The company has incorporated a subsidiary on 3rd September 2025 in the name of Loire Cosmetics Limited with 50.75% of share holidng in the same company.

25 Balances of some debtors and creditors are subject to their confirmations.

26 As per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements.

27 Previous year/period's figures have been regrouped/reclassified wherever necessary to correspond with the current period's classification for comparison.

28 As the Company's business activity falls within a single primary business segment i.e. the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

Significant Accounting Policies and Notes to the Financial Statements **1 to 22**

As per our attached Report of Even Date

For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN : 002249N)

SANJAY GARG
Partner
Membership No.: 088636
UDIN : 26088636LMKIWV2895
Place : New Delhi
Date: 29-May-2026

For **and on behalf of the Board of Directors of**
Grande Etoile Pharmaceuticals Limited

For Grande Etoile Pharmaceuticals Ltd. Director

Harsh Mittal
DIN:- 10891142
Director

For Grande Etoile Pharmaceuticals Ltd Director

Vaibhav Kashinath Chaudhari
DIN:- 05270401
Director